Abstracts tagged "Biologicals"

Abstract Number: 1460 • ACR Convergence 2025
Effect of Guselkumab and IL-17 Inhibitors on Work Productivity and Activity Impairment in Psoriatic Arthritis: 6-Month Results of the PsABIOnd Observational Study
Stefan Siebert¹, Mohamed Sharaf², Frank Behrens³, Proton Rahman⁴, mitsumasa kishimoto⁵, Enrique R. Soriano⁶, Emmanouil Rampakakis⁷, László Köleséri⁸, Karissa Lozenski⁹, Ruben Queiro¹⁰, Ennio Lubrano¹¹ and Laure Gossec¹², ¹University of Glasgow, Glasgow, United Kingdom, ²Janssen - Johnson & Johnson, Dubai, United Arab Emirates, ³Goethe-University & Fraunhofer ITMP, Frankfurt, Germany, ⁴Division of Rheumatology, Craig L. Dobbin Genetics Research Centre, Discipline of Medicine, Memorial University of Newfoundland, St. John's, Canada, ⁵Kyorin University School of Medicine, Tokyo, Japan, ⁶Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires and University Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁷JSS Medical Research, Montréal, QC, Canada, ⁸IQVIA, Budapest, Hungary, ⁹Johnson & Johnson, Horsham, PA, ¹⁰Hospital Universitario Central de Asturias, Oviedo. Asturias, Spain, ¹¹Department of Medicine, Università deglia Studi del Molise, CAMPOBASSO, Italy, ¹²Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France
Background/Purpose: Work impairment is a key issue in PsA. Biologic treatments can improve work status in patients (pts) with PsA; however, there is lack of…
Abstract Number: 1356 • ACR Convergence 2025
Use of (MSB11456), the first tocilizumab biosimilar approved for rheumatoid arthritis: 6-month data from an international observational study
Jonathan Kay¹, Eugen feist², Ernest Choy³, Joerg Kaufmann⁴, Ernest Wong⁵, Hector Corominas⁶, René-Marc Flipo⁷, Jérôme Avouac⁸, María América López Lasanta⁹, Joelle Monnet¹⁰, Peter Baker¹¹, Maria Romanova Michailidi¹², Fabrizio Dolfi¹¹ and Graziella Pourcel¹³, ¹UMass Chan Medical School, Worcester, MA, ²Helios Department of Rheumatology, Vogelsang-Gommern, Germany, ³Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, United Kingdom, ⁴NA, Ludwigsfelde, Germany, ⁵Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom, ⁶Hospital de Sant Pau, Barcelona, Spain, ⁷Université de Lille, CHU Lille, Service de rhumatologie, Lille, France, Lille, France, ⁸Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ⁹Hospital Universitario Vall d´Hebron, Barcelona, Spain, ¹⁰Fresenius Kabi SwissBioSim, Eysins, Switzerland, ¹¹Fresenius Kabi Biopharma, Eysins, Switzerland, ¹²University of Geneva, Eysins, Switzerland, ¹³Fresenius Kabi Biopharma, Eyzins, France
Background/Purpose: Although most healthcare professionals are convinced of the quality, safety, and favorable economic impact of biosimilars, their routine use is not yet widespread. MSB11456…
Abstract Number: 1122 • ACR Convergence 2025
A Retrospective Study of Adverse Cardiovascular Events in Patients Started on JAK Inhibitors at Two Major Health Systems in Northeast Ohio: Analysis of the 2019 JAK Inhibitors FDA Boxed Warning for Increased Risk of Serious Heart-Related Problems
William Koch¹, Donald Anthony², Janeen Leon² and Nora G. Singer², ¹University Hospitals Parma Medical Center, Parma, OH, ²The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Janus kinase (JAK) inhibitors are immunosuppressive medications that target the JAK-STAT signaling pathway. Tofacitinib (Xeljanz) was the first JAK inhibitor approved for the treatment…
Abstract Number: 0667 • ACR Convergence 2025
Retrospective Chart Audit Reveals Gaps in Steroid Tapering and Use of ACR Guideline-Recommended Regimens in LN
Sawyer May¹, Lynn Price¹ and Ryan Rex², ¹Spherix Global Insights, Exton, PA, ²Spherix Global Insights, Chester Springs, PA
Background/Purpose: In May 2025, ACR released updated recommendations for the management of LN2. Notably, since the previous guidelines update in 2012, the FDA has approved…
Abstract Number: 0875 • ACR Convergence 2025
Efficacy and Safety of Icotrokinra, a Novel Targeted Oral Peptide (IL-23R-Inhibitor), in Adolescents With Moderate-to-Severe Plaque Psoriasis: Subgroup Analyses From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (ICONIC-LEAD)
Lawrence Eichenfield¹, Ricardo Galimberti², Adelaide Hebert³, Wen-Hui Wang⁴, Jennifer Soung⁵, Nina Magnolo⁶, John Browning⁷, Angela Moore⁸, Mark Lebwohl⁹, Dagmar Wilsmann-Theis¹⁰, Joseph F Merola¹¹, Georgios Kokolakis¹², Dariusch Mortazawi¹³, Parbeer Grewal¹⁴, Megan Miller¹⁵, Joseph Cafone¹⁶, Shu Li¹⁷, Gigi Jiang¹⁷, Fabio Nunes¹⁷, Cynthia DeKlotz¹⁸ and Amy Paller¹⁹, ¹University of California, San Diego School of Medicine, La Jolla, CA, USA, La Jolla, CA, ²Hosp Italiano de Buenos Aires, Buenos Aires, Argentina, Buenos Aires, Argentina, ³University of Texas Medical School-Houston, Bellaire, TX, USA, Bellaire, TX, ⁴Peking University Third Hospital, Haidian District, Beijing, China, Beijing, China (People's Republic), ⁵Southern California Dermatology, Inc, Santa Ana, CA, USA, Santa Ana, ⁶University Hospital Muenster, Muenster, Germany, Muenster, Germany, ⁷Methodist Children's Hospital, San Antonio, TX, USA, San Antonio, TX, ⁸Baylor University Medical Center, Dallas, TX, USA, Dallas, TX, ⁹Icahn School of Medicine at Mount Sinai, New York, NY, ¹⁰University Hospital Bonn, Center for Skin Diseases, Bonn, Germany, Bonn, Germany, ¹¹Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ¹²Charité-Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany, ¹³Clinical Research Center, Remscheid, Germany, Remscheid, Germany, ¹⁴University of Alberta, Edmonton, Alberta, Canada, Edmonton, AB, Canada, ¹⁵Johnson & Johnson, San Diego, CA, USA, San Diego, CA,, CA, ¹⁶Johnson & Johnson, San Diego, CA, USA, San Diego, CA, CA, ¹⁷Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ¹⁸Johnson & Johnson, San Diego, CA, USA, San Diego, CA, ¹⁹Northwestern University Feinberg School of Medicine, Chicago, IL, USA, Chicago, IL
Background/Purpose: Icotrokinra (ICO), a novel targeted oral peptide, binds the interleukin (IL)-23 receptor to inhibit IL-23 signaling. ICONIC-LEAD (NCT06095115) is the first Phase 3 study…
Abstract Number: 0493 • ACR Convergence 2025
Phase I Trial in Participants with Rheumatoid Arthritis and Healthy Volunteers with CIT-013, a First in Class NETosis Inhibitor
Maarten Kraan¹, Salah Hadi², Leonie Middelink³, Renato Chirivi³, Eric meldrum³, Naomi Klarenbeek⁴ and Patrick Round³, ¹Citryll BV, Den Dolder, Netherlands, ²ICON Netherlands BV, Groningen, Netherlands, ³Citryll BV, Oss, Netherlands, ⁴CHDR, Leiden, Netherlands
Background/Purpose: Aberrant Neutrophil Extracellular Trap (NET) production contributes to the pathophysiology of multiple inflammatory and autoimmune diseases including rheumatoid arthritis (RA). We report data of…
Abstract Number: 0205 • ACR Convergence 2025
Implementation of the Varicella Zoster virus vaccine and its Real-World effectiveness
Laura Mas Sanchez¹, ELENA GRAU GARCIA², Carlos Valera Ribera³, Pablo Muñoz-Martínez⁴, Daniel Ramos Castro⁵, Alba Maria Torrat Noves⁶, Belen Villanueva Manes⁷, Iago Alcántara Álvarez⁸, Miguel Simeo Vinaixa⁹, Andres Perez Hurtado¹⁰ and José Andrés Román Ivorra¹¹, ¹Hospital Universitari i Politecnic La Fe, València, Spain, ²HUP La Fe, Valencia, Comunidad Valenciana, Spain, ³Hospital Universitario Doctor Peset, València, Spain, ⁴Hospital Universitario y Politécnico La Fe, Sagunto, Spain, ⁵Hospital Universitari i Politecnic La Fe, Valencia, Spain, ⁶Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Spain, ⁷Hospital La Fe, València, Spain, ⁸Hospital Universitari i Politénic La Fe, València, Spain, ⁹Rheumatology Department. HUP La Fe, Valencia, Spain, ¹⁰Hospital Universitario y Politècnico La Fe, València, Comunidad Valenciana, Spain, ¹¹Hospital Universitari i Politècnic La Fe, Valencia, Spain
Background/Purpose: In 2023, Spain approved the inactivated varicella zoster virus (VZV) vaccine in individuals over 50 years of age with immunosuppressive conditions, including rheumatology patients…
Abstract Number: 2689 • ACR Convergence 2025
Comparison of Incidence of Psoriatic Arthritis in Patients With Psoriasis Treated With Interleukin-17 Inhibitors vs Interleukin-23 Inhibitors, Interleukin-12/23 Inhibitors, and Tumor Necrosis Factor Inhibitors in Real-World Practice: A Retrospective Study
April Armstrong¹, Joseph Merola², Gang Wang³, Ariane Faucher⁴, Riley Taiji⁴, Francis Vekeman⁴, Alexis Shew⁵, Tim Nguyen⁵ and Laura Coates⁶, ¹University of California Los Angeles, Los Angeles, CA, USA, Los Angeles, CA, ²UT Southwestern Medical Center, Dallas, TX, ³Department of Dermatology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China (People's Republic), ⁴STATLOG, Inc, Montreal, QC, Canada, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom
Background/Purpose: Biologic therapies for moderate to severe psoriasis (PsO) include inhibitors of IL-17 (IL-17i), IL-23i, IL-12/23i, and tumor necrosis factor (TNFi). Previous studies that assessed…
Abstract Number: 2464 • ACR Convergence 2025
IMC-002 (IMM0306), a First-in-Class Bi-specific Fusion Protein, Demonstrates Improvements in Systemic Lupus Erythematosus (SLE) Disease Activity Measures and Biomarkers in Patients with Moderate to Severe Active SLE in the Open-label Phase 1b/2 Study
Haihong Yao¹, Wenzhi Tian², Qian Zheng², Min Chen², Guoping Jiang³, Zhichun Liu⁴, Yingkun Nie⁵, Rui Wu⁶, Zhaohui Zheng⁷ and Zhanguo Li¹, ¹Peking University People's Hospital, Beijing, China (People's Republic), ²ImmuneCare Biopharmaceuticals (Shanghai) Co.,Ltd, Shanghai, China (People's Republic), ³Jilin Province People's Hospital, Changchun, China (People's Republic), ⁴The Second Affiliated Hospital of Soochow, Suzhou, China (People's Republic), ⁵The Second Affiliated Hospital of Harbin Medical University, Haerbin, China (People's Republic), ⁶The First Affiliated Hospital of Nanchang University, Nanchang, China (People's Republic), ⁷The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China (People's Republic)
Background/Purpose: Deep B cell depletion has been confirmed to be the main mechanism for complete clinical response of SLE patients. We analyzed the peripheral blood…
Abstract Number: 2344 • ACR Convergence 2025
Impact of Bimekizumab Use in Spondyloarthritis and Psoriatic Arthritis: Persistence Study in Routine Clinical Practice in Spain (BIMPACT study)
Cristina Valero¹, Chamaida Plasencia-Rodríguez², Maria Beatriz Paredes Romero³, Silvia Montes⁴, Josefina Marin⁵, Aranzazu Rubio⁶, Cristina Macía-Villa⁷, Laura Gonzalez Hombrado⁸, Maria Luisa Gonzalez Gomez⁹, Maria Carmen Ortega de la O¹⁰, Mercedes Morcillo Valle¹¹, Rosario Garcia Vicuña¹², EVA GLORIA TOMERO MURIEL¹², Diana Peiteado² and BEATRIZ JOVEN¹³, ¹Hospital de la Princesa, Madrid, Spain, ²Hospital Universitario La Paz, MADRID, Spain, ³Infanta Sofía University Hospital, Madrid, Spain, ⁴Hospital de Talavera, Talavera, Castilla-La Mancha, Spain, ⁵Hospital Universitario Rey Juan Carlos, Madrid, Spain, ⁶Hospital Universitario Infanta Cristina, Madrid, Spain, ⁷Hospital Universitario Ramon y Cajal, Madrid, Spain, ⁸Hospital Universitario del Tajo, Aranjuez (MADRID), Madrid, Spain, ⁹Hospital Universitario El Escorial, Majadahonda, Spain, ¹⁰Hospital Universitario Getafe, Madrid, Madrid, Spain, ¹¹Hospital El Escorial, San Lorenzo de El Es, Spain, ¹²Hospital Universitario de la Princesa, Madrid, Spain, ¹³H. Universitario ¹² Octubre, Madrid, Spain
Background/Purpose: Bimekizumab (BKZ) is a monoclonal antibody that simultaneously blocks IL-17A, IL-17F, and their heterodimer, key cytokines involved in the pathogenesis of spondyloarthritis (SpA) and…
Abstract Number: 2038 • ACR Convergence 2025
Real-World Use of Dual Targeted Therapy in Rheumatic Disease: A Single-Center Case Series
Marta Aguilar Zamora¹, Karla Romelia Arévalo Ruales², marta Garijo Bufort², Maria Isabel Pastor Orduña¹, Celia Aparicio Rubio³, Silvia Cornejo Uixeda⁴ and Joaquín Borrás Blasco⁴, ¹Rheumatology Department, Hospital de Sagunto, Spain, Puerto de Sagunto, Comunidad Valenciana, Spain, ²Rheumatology Department, Hospital de Sagunto, Spain, valencia, Spain, ³Pharmacy Department, Hospital de Sagunto, Spain, Puerto de Sagunto, ⁴Pharmacy Department, Hospital de Sagunto, Spain, Puerto de Sagunto, Spain
Background/Purpose: Combination therapy with two biologic agents (bDMARDs) or a biologic plus a Janus kinase inhibitor (JAKi) is rarely used in rheumatology due to safety…
Abstract Number: 1597 • ACR Convergence 2025
Effectiveness and Safety of Rituximab Biosimilars in Small Vessel Vasculitis: a Systematic Literature Review
Caitlyn Kanters¹, Joo Young Lee², Christian Pagnoux³, Lillian Barra⁴, Jean-Paul Makhzoum⁵ and Arielle Mendel⁶, ¹McGill University, Montreal, Canada, ²Research institute of the McGill University Health Center, Montreal, QC, Canada, ³Mount Sinai Hospital, University Health Network, Toronto, and Canadian Vasculitis Research Network (CanVasc), Toronto, ON, Canada, ⁴Western University, London, ON, Canada, ⁵University of Montreal, Montreal, ⁶McGill University Health Centre, Montreal, Canada
Background/Purpose: To evaluate the safety and effectiveness of rituximab biosimilars in the treatment of small vessel vasculitis.Methods: The Medline, CINAHL, Cochrane, Embase and Web of…
Abstract Number: 1459 • ACR Convergence 2025
Fungal Infections, Including Candida, in Patients With Active Psoriatic Arthritis (PsA) Treated With Secukinumab: A Pooled Analysis of 9 Phase 3 Trials
Shikha Singla¹, Linda Grinnell-Merrick², Weibin Bao³, Artem Zharkov⁴ and Abhijeet Danve⁵, ¹Medical College of Wisconsin, Milwaukee, WI, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³Novartis Pharmaceuticals Corporation, Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Section of Rheumatology, Department of Medicine, Yale School of Medicine, New Haven, CT
Background/Purpose: PsA is a chronic inflammatory disease characterized by joint pain, swelling and stiffness, and is often accompanied by cutaneous changes linked to psoriasis. Patients…
Abstract Number: 1353 • ACR Convergence 2025
Phase 3 Study of the Efficacy, Safety and Immunogenicity of the Proposed Tocilizumab Biosimilar RGB-19, Intravenously Administered to Participants With Active Rheumatoid Arthritis: 52-Week Data
Gerd Burmester¹, Hiroaki Matsuno², Ernest Choy³, Masato Okada⁴, Roshan Dias⁵, Károly Horvát-Karajz⁵, Gordana Dancer⁵, Yusuke Karibe⁶, Suguru Masuda⁶, Joachim Kiefer⁵ and Paul Emery⁷, ¹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Matsuno Clinic for Rheumatic Disease, Toyama, and Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ³Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, United Kingdom, ⁴Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ⁵Gedeon Richter Plc, Budapest, Hungary, ⁶Mochida Pharmaceutical Co., Ltd, Tokyo, Japan, ⁷University of Leeds, Leeds, England, United Kingdom
Background/Purpose: RGB-19 is a proposed biosimilar to tocilizumab, a monoclonal antibody that competitively inhibits the binding of interleukin-6 (IL-6) to its receptor. Results of a…
Abstract Number: 1116 • ACR Convergence 2025
Second-line Therapy for Immune-checkpoint Inhibitor-induced Pneumonitis
Sarah Sun¹, Cathryn Lee² and Pankti Reid³, ¹University of Chicago, Chicago, IL, ²University of Chicago, Chicago, ³University of Chicago Medical Center, Chicago, IL
Background/Purpose: Immune checkpoint inhibitors (ICIs) used for cancer therapy can have varied toxicities among which pneumonitis (ICI-pneumonitis) is a rare (< 5%) but often fatal…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].